Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash & Equivalents (2018 - 2025)

AVITA Medical's Cash & Equivalents history spans 8 years, with the latest figure at $8.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 40.21% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $8.4 million, down 40.21%, while the annual FY2025 figure was $8.4 million, 40.21% down from the prior year.
  • Cash & Equivalents reached $8.4 million in Q4 2025 per RCEL's latest filing, down from $15.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $115.1 million in Q1 2021 to a low of $8.4 million in Q4 2025.
  • Average Cash & Equivalents over 5 years is $31.2 million, with a median of $20.4 million recorded in 2023.
  • Peak YoY movement for Cash & Equivalents: tumbled 85.58% in 2022, then surged 94.84% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $51.1 million in 2021, then tumbled by 72.41% to $14.1 million in 2022, then skyrocketed by 56.87% to $22.1 million in 2023, then crashed by 36.48% to $14.0 million in 2024, then crashed by 40.21% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Cash & Equivalents are $8.4 million (Q4 2025), $15.4 million (Q3 2025), and $10.6 million (Q2 2025).